Experience That Can’t Be Replicated | Amgen Oncology Biosimilars

Oncology Biosimilars with Amgen— Your Complete Partner

We’ve invested ~ $2 billion in our biosimilars as part of our long-term commitment to help create a more economically sustainable healthcare system1

The Leading Oncology Biosimilars Portfolio That Continues To Grow

The #1 prescribed
bevacizumab biosimilar3,

Please see MVASI® full
Prescribing Information

NOW
AVAILABLE

*Data collected from Q3 2019 to Q3 2020. Data collected from April 2020 to October 2020.

Real-world evidence that can't be replicated5-11

Innovator Oncology PORTFOLIO

10

products, including therapeutic & supportive care

SUPPLY

0

SHORTAGES

including biosimilars, for more than a decade through natural disasters and during COVID-19

FAVORABLE
COVERAGE

>79%

of lives covered—unrestricted, with no step edit required for KANJINTI® and MVASI®§

Patients
Treated

~130k

with Amgen Biosimilars

GLOBAL
Network

100

countries in the manufacturing & distribution network

Patients
SUPPORTED

3400+

by Amgen Assist 360 for MVASI® and KANJINTI®**

  • Between 2007 to October 2020.
  • §From MMIT coverage in September 2020 for KANJINTI® and MVASI®. Covered is defined as covered with no step edit. The data represents plan participants enrolled in commercial and Medicare Advantage plans.
  • **As of Sept 2020.
callout-new-copy

At Amgen, we understand healthcare practice economics. That's why we're a proven long-term partner

See how your peers are experiencing
Amgen Oncology Biosimilars—watch the video below

Heritage

"I was actually very excited [about Amgen Biosimilars] because Amgen has a very long experience in manufacturing biologics."

EXPERTISE

"I want a manufacturer who's got experience and has got enough scale to supply me with the product in an uninterrupted fashion. My patients deserve that and need that."

Dr Lee Schwartzberg, Oncologist

COMMITMENT

"When we choose a manufacturer, we look at product portfolio. If they are heavy in oncology and biologics, then we know that they know what they're doing."

SUPPORT

"Amgen does have a large support network and plenty of data available to help guide providers and pharmacists through some of these switches over from the reference product to a biosimilar."

Chris Marcum, Pharmacist
callout-hex-2

Learn more about the Amgen
Biosimilars development program

Pipeline of 3 biosimilars across therapeutic areas

Additional resources

download-1

Learn more about Amgen Biosimilars

References: 1. Data on file, Amgen [$2 Billion Invested]; 2019. 2. Data on file, Amgen [#1 Trastuzumab Biosimilar]; 2020. 3. Data on file, Amgen [#1 Bevacizumab Biosimilar]; 2020. 4. RIABNI™ (rituximab-arrx) Prescribing Information, Amgen. 5. Amgen Oncology. Products. www.amgenoncology.com. Accessed November 17, 2020. 6. Data on file, Amgen; 2018. 7. Data on file, Amgen; 2020. 8. Data on file, Amgen [Payer Coverage]; 2020. 9. Data on file, Amgen [Amgen Biosimilars Patients Worldwide]; 2020. 10. Amgen. About Amgen: Fact Sheet. www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx. Accessed November 17, 2020. 11. Data on file, Amgen [AA360]; 2020.